Biotech Vaxart (VXRT) has announced positive pre-clinical results for its oral COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose.
Shares have surged 35% in pre-market trading Tuesday, with the stock’s year-to-date gain already at an eye-watering 567%.
“These early pre-clinical results are in line with those for our oral influenza vaccine which was protective in a clinical Phase 2 efficacy study,” said Sean Tucker, Ph.D., CSO of Vaxart, adding that additional data will inform which candidate moves forward into clinical trials. Source smarteranalysis
Shares have surged 35% in pre-market trading Tuesday, with the stock’s year-to-date gain already at an eye-watering 567%.
“These early pre-clinical results are in line with those for our oral influenza vaccine which was protective in a clinical Phase 2 efficacy study,” said Sean Tucker, Ph.D., CSO of Vaxart, adding that additional data will inform which candidate moves forward into clinical trials. Source smarteranalysis
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media
1) Download our Mobile App >>
Android: dexwirenews.com/APP
Apple: dexwirenews.com/iOS
2) Join our Telegram >> t.me/DEXWireNews
3) Follow @DEXWireNews on Social Media